Back to Newsroom

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass.April 6, 2018 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that on April 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 250,000 shares of Curis common stock to three new employees, with a grant date of April 2, 2018 (the “Q2 2018 Inducement Grants”).
READ MORE…